Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients
Kevin T. Savage, Monica Rosales Santillan, Kelsey S. Flood, Alexandra Charrow, Martina L. Porter, Alexa B. Kimball
Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by inflammatory nodules, abscesses, and fistulae. Severe disease is frequently treated with adalimumab or infliximab, but limited research and insurance coverage confine treatment options. Often, aggressive multifaceted therapeutic regimens fail in severe cases.
Topics & Concepts
Hidradenitis suppurativaMedicineAdalimumabInfliximabTofacitinibDermatologyDiseasePsoriasisInternal medicineRheumatoid arthritisHidradenitis Suppurativa and TreatmentsColorectal and Anal CarcinomasAutoimmune and Inflammatory Disorders